{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T15:15:14Z","timestamp":1794582914222,"version":"4.9.1"},"reference-count":34,"publisher":"American Society of Hematology","issue":"8","license":[{"start":{"date-parts":[[2024,1,19]],"date-time":"2024-01-19T00:00:00Z","timestamp":1705622400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,4,23]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Iron plays a major role in the deterioration of \u03b2-thalassemia. Indeed, the high levels of transferrin saturation and iron delivered to erythroid progenitors are associated with production of \u03b1-globin precipitates that negatively affect erythropoiesis. Matriptase-2\/TMPRSS6, a membrane-bound serine protease expressed in hepatocytes, negatively modulates hepcidin production and thus is a key target to prevent iron overload in \u03b2-thalassemia. To address safety concerns raised by the suppression of Tmprss6 by antisense oligonucleotides or small interfering RNA, we tested a fully human anti-matriptase-2 antibody, RLYB331, which blocks the protease activity of matriptase-2. When administered weekly to Hbbth3\/+ mice, RLYB331 induced hepcidin expression, reduced iron loading, prevented the formation of toxic \u03b1-chain\/heme aggregates, reduced ros oxygen species formation, and improved reticulocytosis and splenomegaly. To increase the effectiveness of RLYB331 in \u03b2-thalassemia treatment even further, we administered RLYB331 in combination with RAP-536L, a ligand-trapping protein that contains the extracellular domain of activin receptor type IIB and alleviates anemia by promoting differentiation of late-stage erythroid precursors. RAP-536L alone did not prevent iron overload but significantly reduced apoptosis in the erythroid populations of the bone marrow, normalized red blood cell counts, and improved hemoglobin and hematocrit levels. Interestingly, the association of RLYB331 with RAP-536L entirely reversed the \u03b2-thalassemia phenotype in Hbbth3\/+ mice and simultaneously corrected iron overload, ineffective erythropoiesis, splenomegaly, and hematological parameters, suggesting that a multifunctional molecule consisting of the fusion of RLYB331 with luspatercept (human version of RAP-536L) would allow administration of a single medication addressing simultaneously the different pathophysiological aspects of \u03b2-thalassemia.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2023012010","type":"journal-article","created":{"date-parts":[[2024,1,19]],"date-time":"2024-01-19T20:01:16Z","timestamp":1705694476000},"page":"1898-1907","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":10,"title":["A human anti-matriptase-2 antibody limits iron overload, \u03b1-globin aggregates, and splenomegaly in \u03b2-thalassemic mice"],"prefix":"10.1182","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-7677-0995","authenticated-orcid":false,"given":"Matthew","family":"Wake","sequence":"first","affiliation":[{"name":"1Kymab Ltd, Babraham Research Campus, Cambridge, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana\u00efs","family":"Palin","sequence":"additional","affiliation":[{"name":"2Institut de Recherche en Sant\u00e9 Digestive, Universit\u00e9 de Toulouse, INSERM, Institut National de Recherche pour l'Agriculture, l'alimentation et l'Environnement, \u00c9cole Nationale V\u00e9t\u00e9rinaire de Toulouse, Universit\u00e9 Paul Sabatier, Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0967-0636","authenticated-orcid":false,"given":"Audrey","family":"Belot","sequence":"additional","affiliation":[{"name":"2Institut de Recherche en Sant\u00e9 Digestive, Universit\u00e9 de Toulouse, INSERM, Institut National de Recherche pour l'Agriculture, l'alimentation et l'Environnement, \u00c9cole Nationale V\u00e9t\u00e9rinaire de Toulouse, Universit\u00e9 Paul Sabatier, Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathieu","family":"Berger","sequence":"additional","affiliation":[{"name":"2Institut de Recherche en Sant\u00e9 Digestive, Universit\u00e9 de Toulouse, INSERM, Institut National de Recherche pour l'Agriculture, l'alimentation et l'Environnement, \u00c9cole Nationale V\u00e9t\u00e9rinaire de Toulouse, Universit\u00e9 Paul Sabatier, Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megane","family":"Lorgouilloux","sequence":"additional","affiliation":[{"name":"2Institut de Recherche en Sant\u00e9 Digestive, Universit\u00e9 de Toulouse, INSERM, Institut National de Recherche pour l'Agriculture, l'alimentation et l'Environnement, \u00c9cole Nationale V\u00e9t\u00e9rinaire de Toulouse, Universit\u00e9 Paul Sabatier, Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margot","family":"Bichon","sequence":"additional","affiliation":[{"name":"2Institut de Recherche en Sant\u00e9 Digestive, Universit\u00e9 de Toulouse, INSERM, Institut National de Recherche pour l'Agriculture, l'alimentation et l'Environnement, \u00c9cole Nationale V\u00e9t\u00e9rinaire de Toulouse, Universit\u00e9 Paul Sabatier, Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Papworth","sequence":"additional","affiliation":[{"name":"1Kymab Ltd, Babraham Research Campus, Cambridge, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luke","family":"Bayliss","sequence":"additional","affiliation":[{"name":"1Kymab Ltd, Babraham Research Campus, Cambridge, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Grimshaw","sequence":"additional","affiliation":[{"name":"1Kymab Ltd, Babraham Research Campus, Cambridge, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6787-8534","authenticated-orcid":false,"given":"Natalie","family":"Rynkiewicz","sequence":"additional","affiliation":[{"name":"1Kymab Ltd, Babraham Research Campus, Cambridge, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jemima","family":"Paterson","sequence":"additional","affiliation":[{"name":"1Kymab Ltd, Babraham Research Campus, Cambridge, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia","family":"Poindron","sequence":"additional","affiliation":[{"name":"1Kymab Ltd, Babraham Research Campus, Cambridge, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"Spearing","sequence":"additional","affiliation":[{"name":"1Kymab Ltd, Babraham Research Campus, Cambridge, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Carter","sequence":"additional","affiliation":[{"name":"1Kymab Ltd, Babraham Research Campus, Cambridge, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robyne","family":"Hudson","sequence":"additional","affiliation":[{"name":"1Kymab Ltd, Babraham Research Campus, Cambridge, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Millie","family":"Campbell","sequence":"additional","affiliation":[{"name":"1Kymab Ltd, Babraham Research Campus, Cambridge, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9205-1440","authenticated-orcid":false,"given":"Verena","family":"Petzer","sequence":"additional","affiliation":[{"name":"3Department of Internal Medicine II, Medical University of Innsbruck, Innsbruck, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8518-5056","authenticated-orcid":false,"given":"C\u00e9line","family":"Besson-Fournier","sequence":"additional","affiliation":[{"name":"2Institut de Recherche en Sant\u00e9 Digestive, Universit\u00e9 de Toulouse, INSERM, Institut National de Recherche pour l'Agriculture, l'alimentation et l'Environnement, \u00c9cole Nationale V\u00e9t\u00e9rinaire de Toulouse, Universit\u00e9 Paul Sabatier, Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chlo\u00e9","family":"Latour","sequence":"additional","affiliation":[{"name":"2Institut de Recherche en Sant\u00e9 Digestive, Universit\u00e9 de Toulouse, INSERM, Institut National de Recherche pour l'Agriculture, l'alimentation et l'Environnement, \u00c9cole Nationale V\u00e9t\u00e9rinaire de Toulouse, Universit\u00e9 Paul Sabatier, Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Am\u00e9lie","family":"Largounez","sequence":"additional","affiliation":[{"name":"2Institut de Recherche en Sant\u00e9 Digestive, Universit\u00e9 de Toulouse, INSERM, Institut National de Recherche pour l'Agriculture, l'alimentation et l'Environnement, \u00c9cole Nationale V\u00e9t\u00e9rinaire de Toulouse, Universit\u00e9 Paul Sabatier, Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oph\u00e9lie","family":"Gourbeyre","sequence":"additional","affiliation":[{"name":"2Institut de Recherche en Sant\u00e9 Digestive, Universit\u00e9 de Toulouse, INSERM, Institut National de Recherche pour l'Agriculture, l'alimentation et l'Environnement, \u00c9cole Nationale V\u00e9t\u00e9rinaire de Toulouse, Universit\u00e9 Paul Sabatier, Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexis","family":"Fay","sequence":"additional","affiliation":[{"name":"2Institut de Recherche en Sant\u00e9 Digestive, Universit\u00e9 de Toulouse, INSERM, Institut National de Recherche pour l'Agriculture, l'alimentation et l'Environnement, \u00c9cole Nationale V\u00e9t\u00e9rinaire de Toulouse, Universit\u00e9 Paul Sabatier, Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7911-6353","authenticated-orcid":false,"given":"H\u00e9l\u00e8ne","family":"Coppin","sequence":"additional","affiliation":[{"name":"2Institut de Recherche en Sant\u00e9 Digestive, Universit\u00e9 de Toulouse, INSERM, Institut National de Recherche pour l'Agriculture, l'alimentation et l'Environnement, \u00c9cole Nationale V\u00e9t\u00e9rinaire de Toulouse, Universit\u00e9 Paul Sabatier, Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Paule","family":"Roth","sequence":"additional","affiliation":[{"name":"2Institut de Recherche en Sant\u00e9 Digestive, Universit\u00e9 de Toulouse, INSERM, Institut National de Recherche pour l'Agriculture, l'alimentation et l'Environnement, \u00c9cole Nationale V\u00e9t\u00e9rinaire de Toulouse, Universit\u00e9 Paul Sabatier, Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor","family":"Theurl","sequence":"additional","affiliation":[{"name":"1Kymab Ltd, Babraham Research Campus, Cambridge, United Kingdom"},{"name":"3Department of Internal Medicine II, Medical University of Innsbruck, Innsbruck, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Volker","family":"Germaschewski","sequence":"additional","affiliation":[{"name":"1Kymab Ltd, Babraham Research Campus, Cambridge, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delphine","family":"Meynard","sequence":"additional","affiliation":[{"name":"2Institut de Recherche en Sant\u00e9 Digestive, Universit\u00e9 de Toulouse, INSERM, Institut National de Recherche pour l'Agriculture, l'alimentation et l'Environnement, \u00c9cole Nationale V\u00e9t\u00e9rinaire de Toulouse, Universit\u00e9 Paul Sabatier, Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2024,4,11]]},"reference":[{"issue":"7","key":"2024042218552242900_bib1","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/ng.2996","article-title":"Identification of erythroferrone as an erythroid regulator of iron metabolism","volume":"46","author":"Kautz","year":"2014","journal-title":"Nat Genet"},{"issue":"1","key":"2024042218552242900_bib2","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/j.1749-6632.2010.05596.x","article-title":"Iron metabolism and ineffective erythropoiesis in beta-thalassemia mouse models","volume":"1202","author":"Ramos","year":"2010","journal-title":"Ann N Y Acad Sci"},{"key":"2024042218552242900_bib3","doi-asserted-by":"crossref","first-page":"938640","DOI":"10.1155\/2010\/938640","article-title":"beta-thalassemia: HiJAKing ineffective erythropoiesis and iron overload","volume":"2010","author":"Melchiori","year":"2010","journal-title":"Adv Hematol"},{"issue":"3","key":"2024042218552242900_bib4","doi-asserted-by":"crossref","first-page":"E57","DOI":"10.1002\/ajh.26055","article-title":"Management of non-transfusion-dependent beta-thalassemia (NTDT): the next 5 years","volume":"96","author":"Musallam","year":"2021","journal-title":"Am J Hematol"},{"issue":"4","key":"2024042218552242900_bib5","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1038\/nm.3512","article-title":"Transforming growth factor-beta superfamily ligand trap ACE-536 corrects anemia by promoting late-stage erythropoiesis","volume":"20","author":"Suragani","year":"2014","journal-title":"Nat Med"},{"issue":"4","key":"2024042218552242900_bib6","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1038\/nm.3468","article-title":"An activin receptor IIA ligand trap corrects ineffective erythropoiesis in beta-thalassemia","volume":"20","author":"Dussiot","year":"2014","journal-title":"Nat Med"},{"issue":"25","key":"2024042218552242900_bib7","doi-asserted-by":"crossref","first-page":"3864","DOI":"10.1182\/blood-2013-06-511238","article-title":"Modified activin receptor IIB ligand trap mitigates ineffective erythropoiesis and disease complications in murine beta-thalassemia","volume":"123","author":"Suragani","year":"2014","journal-title":"Blood"},{"issue":"4","key":"2024042218552242900_bib8","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1172\/JCI66969","article-title":"Reducing TMPRSS6 ameliorates hemochromatosis and beta-thalassemia in mice","volume":"123","author":"Guo","year":"2013","journal-title":"J\u00a0Clin Invest"},{"issue":"7","key":"2024042218552242900_bib9","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood-2012-09-453977","article-title":"An RNAi therapeutic targeting Tmprss6 decreases iron overload in Hfe(-\/-) mice and ameliorates anemia and iron overload in murine beta-thalassemia intermedia","volume":"121","author":"Schmidt","year":"2013","journal-title":"Blood"},{"issue":"2","key":"2024042218552242900_bib10","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1182\/blood-2015-10-676742","article-title":"Minihepcidin peptides as disease modifiers in mice affected by beta-thalassemia and polycythemia vera","volume":"128","author":"Casu","year":"2016","journal-title":"Blood"},{"issue":"1","key":"2024042218552242900_bib11","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1172\/JCI129382","article-title":"Oral ferroportin inhibitor ameliorates ineffective erythropoiesis in a model of beta-thalassemia","volume":"130","author":"Manolova","year":"2019","journal-title":"J\u00a0Clin Invest"},{"issue":"17","key":"2024042218552242900_bib12","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1182\/blood.2019004719","article-title":"Correcting beta-thalassemia by combined therapies that restrict iron and modulate erythropoietin activity","volume":"136","author":"Casu","year":"2020","journal-title":"Blood"},{"issue":"21","key":"2024042218552242900_bib13","doi-asserted-by":"crossref","first-page":"5021","DOI":"10.1182\/blood-2012-01-401885","article-title":"Deletion of TMPRSS6 attenuates the phenotype in a mouse model of beta-thalassemia","volume":"119","author":"Nai","year":"2012","journal-title":"Blood"},{"issue":"1","key":"2024042218552242900_bib14","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1111\/bjh.17428","article-title":"SLN124, a GalNac-siRNA targeting transmembrane serine protease 6, in combination with deferiprone therapy reduces ineffective erythropoiesis and hepatic iron-overload in a mouse model of beta-thalassaemia","volume":"194","author":"Vadolas","year":"2021","journal-title":"Br J Haematol"},{"issue":"11","key":"2024042218552242900_bib15","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1007\/s40265-020-01341-9","article-title":"Beta thalassemia: new therapeutic options beyond transfusion and iron chelation","volume":"80","author":"Motta","year":"2020","journal-title":"Drugs"},{"issue":"5","key":"2024042218552242900_bib16","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.drudis.2017.01.013","article-title":"Safety of antisense oligonucleotide and siRNA-based therapeutics","volume":"22","author":"Chi","year":"2017","journal-title":"Drug Discov Today"},{"issue":"4","key":"2024042218552242900_bib17","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/nbt.2825","article-title":"Complete humanization of the mouse immunoglobulin loci enables efficient therapeutic antibody discovery","volume":"32","author":"Lee","year":"2014","journal-title":"Nat Biotechnol"},{"issue":"13","key":"2024042218552242900_bib18","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1056\/NEJMoa1910182","article-title":"A\u00a0phase 3 trial of luspatercept in patients with transfusion-dependent beta-thalassemia","volume":"382","author":"Cappellini","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"2024042218552242900_bib19","doi-asserted-by":"crossref","first-page":"6162","DOI":"10.1111\/jcmm.15243","article-title":"Smad2\/3-pathway ligand trap luspatercept enhances erythroid differentiation in murine beta-thalassaemia by increasing GATA-1 availability","volume":"24","author":"Martinez","year":"2020","journal-title":"J\u00a0Cell Mol Med"},{"issue":"suppl 1","key":"2024042218552242900_bib20","doi-asserted-by":"crossref","first-page":"3532","DOI":"10.1182\/blood-2019-124075","article-title":"Generation and characterisation of KY1066, a fully human antibody targeting the enzymatic activity of matriptase-2 for the treatment of iron overload in beta thalassemia","volume":"134","author":"Wake","year":"2019","journal-title":"Blood"},{"issue":"8","key":"2024042218552242900_bib21","doi-asserted-by":"crossref","first-page":"e385","DOI":"10.3324\/haematol.2019.236133","article-title":"LJ000328, a novel ALK2\/3 kinase inhibitor, represses hepcidin and significantly improves the phenotype of IRIDA","volume":"105","author":"Belot","year":"2020","journal-title":"Haematologica"},{"key":"2024042218552242900_bib22","first-page":"90","volume-title":"Iron (Methods in Hematology)","author":"Torrance","year":"1980"},{"issue":"6","key":"2024042218552242900_bib23","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1182\/blood.V75.6.1333.1333","article-title":"The role of membrane skeletal-associated alpha-globin in the pathophysiology of beta-thalassemia","volume":"75","author":"Sorensen","year":"1990","journal-title":"Blood"},{"key":"2024042218552242900_bib24","first-page":"157","article-title":"Gel electrophoretic separation of globin chains","volume":"60","author":"Alter","year":"1981","journal-title":"Prog Clin Biol Res"},{"issue":"2","key":"2024042218552242900_bib25","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.blre.2017.10.001","article-title":"What can we learn from ineffective erythropoiesis in thalassemia?","volume":"32","author":"Oikonomidou","year":"2018","journal-title":"Blood Rev"},{"issue":"11","key":"2024042218552242900_bib26","doi-asserted-by":"crossref","first-page":"5027","DOI":"10.1182\/blood-2006-09-048868","article-title":"Ineffective erythropoiesis in beta-thalassemia is characterized by increased iron absorption mediated by down-regulation of hepcidin and up-regulation of ferroportin","volume":"109","author":"Gardenghi","year":"2007","journal-title":"Blood"},{"issue":"16","key":"2024042218552242900_bib27","doi-asserted-by":"crossref","first-page":"4321","DOI":"10.1182\/blood-2011-03-283614","article-title":"beta-thalassemia: a model for elucidating the dynamic regulation of ineffective erythropoiesis and iron metabolism","volume":"118","author":"Ginzburg","year":"2011","journal-title":"Blood"},{"issue":"12","key":"2024042218552242900_bib28","doi-asserted-by":"crossref","first-page":"4466","DOI":"10.1172\/JCI41717","article-title":"Hepcidin as a therapeutic tool to limit iron overload and improve anemia in beta-thalassemic mice","volume":"120","author":"Gardenghi","year":"2010","journal-title":"J\u00a0Clin Invest"},{"issue":"2","key":"2024042218552242900_bib29","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1038\/nm.2073","article-title":"Transferrin therapy ameliorates disease in beta-thalassemic mice","volume":"16","author":"Li","year":"2010","journal-title":"Nat Med"},{"issue":"3","key":"2024042218552242900_bib30","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1586\/ehm.11.22","article-title":"Prospects for a hepcidin mimic to treat beta-thalassemia and hemochromatosis","volume":"4","author":"Parrow","year":"2011","journal-title":"Expert Rev Hematol"},{"issue":"1","key":"2024042218552242900_bib31","doi-asserted-by":"crossref","first-page":"e8","DOI":"10.3324\/haematol.2015.133348","article-title":"Combination of Tmprss6- ASO and the iron chelator deferiprone improves erythropoiesis and reduces iron overload in a mouse model of beta-thalassemia intermedia","volume":"101","author":"Casu","year":"2016","journal-title":"Haematologica"},{"issue":"4","key":"2024042218552242900_bib32","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1002\/ajh.23934","article-title":"Combination therapy with a Tmprss6 RNAi-therapeutic and the oral iron chelator deferiprone additively diminishes secondary iron overload in a mouse model of beta-thalassemia intermedia","volume":"90","author":"Schmidt","year":"2015","journal-title":"Am J Hematol"},{"issue":"5","key":"2024042218552242900_bib33","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/nri2747","article-title":"Strategies and challenges for the next generation of therapeutic antibodies","volume":"10","author":"Beck","year":"2010","journal-title":"Nat Rev Immunol"},{"issue":"19","key":"2024042218552242900_bib34","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1182\/blood-2015-11-681494","article-title":"Limiting hepatic Bmp-Smad signaling by matriptase-2 is required for erythropoietin-mediated hepcidin suppression in mice","volume":"127","author":"Nai","year":"2016","journal-title":"Blood"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/8\/1898\/2222773\/blooda_adv-2023-012010-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/8\/1898\/2222773\/blooda_adv-2023-012010-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,22]],"date-time":"2024-04-22T18:55:52Z","timestamp":1713812152000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/8\/8\/1898\/514677\/A-human-anti-matriptase-2-antibody-limits-iron"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,11]]},"references-count":34,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,4,23]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2023012010","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,11]]}}}